Top Markets
Coin of the day
Immatics biotechnologies GmbH Immatics biotechnologies GmbH

Immatics biotechnologies GmbH

IMTXW
Ранг среди акций #40870
Immatics N.V. operates as a clinical-stage biopharmaceutical firm dedicated to... Immatics N.V. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T cell-redirecting immunotherapies designed to combat cancer, primarily targeting the United States market for treatment applications. Their research and development efforts are concentrated on creating targeted immunotherapies for solid tumors, employing two distinct therapeutic strategies: adoptive cell therapies (ACTs) and antibody-like T-cell receptor (TCR) Bispecifics. Immatics N.V. boasts a robust pipeline of product candidates. Among these are IMA203, an immunotherapy targeting solid tumors, and IMA203CD8, a cell therapy product, both currently undergoing Phase 1b clinical trials. Additionally, their earlier-stage assets include IMA204, designed to target tumor stroma, and IMA30x, an allogeneic cellular therapy candidate, both of which are in preclinical development. The company is also progressing with its TCR Bispecifics portfolio, featuring IMA401 in Phase 1b clinical trials, alongside IMA402 and IMA403, which are presently in preclinical phases. Furthermore, Immatics N.V. has established strategic alliances to bolster its development efforts. These include a partnership with MD Anderson Cancer Center for the advancement of various T cell and TCR-based adoptive cellular therapies, an agreement with Celgene Corporation focused on creating innovative adoptive cell therapies for diverse cancers, and a collaboration with Genmab A/S aimed at developing T cell-engaging bispecific immunotherapies for multiple oncological indications. The company's corporate headquarters are situated in Tübingen, Germany.
Цена акции
$0.0006
Последняя синхронизация: 2025-06-30
Рыночная капитализация
$69.91K
Изменение (1 день)
-88.46%
Изменение (1 год)
0.00%
Страна
US
Торговля Immatics biotechnologies GmbH (IMTXW)

Категория

цена IMTXW с рыночной капитализацией B
Immatics biotechnologies GmbH Immatics biotechnologies GmbH
IMTXW
$0.0006
Рыночная капитализация Immatics biotechnologies GmbH(IMTXW)
Рыночная капитализация: $69.91K
По состоянию на August 2026 рыночная капитализация Immatics biotechnologies GmbH составляет $69.91K. Согласно нашим данным, Immatics biotechnologies GmbH занимает 40870th место среди самых ценных компаний мира по рыночной капитализации. Рыночная капитализация — это общая рыночная стоимость всех находящихся в обращении акций публичной компании и обычно используется для оценки ее стоимости.
История рыночной капитализации Immatics biotechnologies GmbH с 2020 по 2026
IMTXW по сравнению с пятеркой самых популярных stocks
Цена за IMTXW Актив Б Рыночная капитализация B результаты
Immatics biotechnologies GmbH Immatics biotechnologies GmbH
$46,806.96 $69.91K
$5.453T +7,801,160,394.09%
Immatics biotechnologies GmbH Immatics biotechnologies GmbH
$38,234.27 $69.91K
$4.455T +6,372,378,373.25%
Immatics biotechnologies GmbH Immatics biotechnologies GmbH
$35,806.69 $69.91K
$4.172T +5,967,782,103.10%
Immatics biotechnologies GmbH Immatics biotechnologies GmbH
$31,525.61 $69.91K
$3.673T +5,254,267,498.63%
Immatics biotechnologies GmbH Immatics biotechnologies GmbH
$24,571.17 $69.91K
$2.863T +4,095,194,984.15%